https://www.selleckchem.com/products/bay-876.html To determine the current role of bisantrene, an anthracene with anthracycline-like activity which was shown in earlier studies to be effective therapy in relapsed/refractory acute myeloid leukemia with no discernible cardiotoxicity, in the treatment of patients with R/R AML. This phase 2, single-center study (NCT03820908) enrolled adult R/R AML to receive bisantrene (250mg/m daily for 7days) which was administered via an intravenous infusion over 2hours on days 1-7. Disease assessment included routine blood work and bone marrow studies. In all, 10 patients were enrolled with a median of 3 lines of prior therapy including seven patients who had relapsed following allogeneic stem cell transplantation. The most frequently reported grade ≥3 treatment-attributed hematologic AE was thrombocytopenia, whereas the most frequently reported grade ≥3 treatment-attributed non-hematologic AE was mucositis. Of the 10 patients, one (10%) achieved a complete remission and three patients achieved a partial remission resulting in an overall response rate of 40%. Next-generation sequencing of patient samples identified a wide array of mutations associated with activated signaling, splicing, and epigenetic modification. In view of the observed low toxicity, a follow-up study combining bisantrene with complementary anti-leukemic therapy is planned. In view of the observed low toxicity, a follow-up study combining bisantrene with complementary anti-leukemic therapy is planned.By analyzing the gene expression of endometrial carcinoma (EC) patients, the key factors in PI3K signaling pathway and its related genes mediating EC were explored. The EC samples and normal endometrial samples were downloaded from TCGA database and GTEx database. The R language "limma" package was used for differential analysis, and the expression level of genes in each tissue was analyzed by "gganatogram" package. Functional enrichment analysis of differential genes